Tyme Technologies Inc Watch

EX-10.2

from 8-K 3 pages Second Amendment to Release Agreement

12/34/56

EX-10.1

from 8-K 10 pages September 2, 2022 [Executive] [Address] [Address] Dear [___]

12/34/56

EX-10.1

from 8-K 3 pages Tyme Technologies, Inc. 2016 Stock Option Plan for Non-Employee Directors Nonqualified Stock Option Award Agreement

12/34/56

EX-10.2

from 8-K 11 pages Syros Pharmaceuticals, Inc. [Form Of] Support Agreement

12/34/56

EX-10.1

from 8-K 11 pages Tyme Technologies, Inc. [Form Of] Support Agreement

12/34/56

EX-10.25

from 10-K 28 pages Mr. Frank Porfido [Redacted] [Redacted]

12/34/56

EX-10.23

from 10-K 4 pages Release Agreement Amendment

12/34/56

EX-10.22

from 10-K 14 pages Voting Agreement

12/34/56

EX-10.20

from 10-K 10 pages Voting Agreement

12/34/56

EX-10.19

from 10-K 12 pages Release Agreement

12/34/56

EX-10.3

from 8-K 2 pages April 28, 2022 [Name] [Address] Dear [Name]: In Exchange for Your Commitments to Tyme Technologies, Inc. (The “Company”) and Your Anticipated Future Contributions, the Company Is Pleased to Offer You the Following Retention Benefits

12/34/56

EX-10.2

from 8-K 13 pages Tyme Technologies, Inc. Indemnification Agreement

12/34/56

EX-10.1

from 8-K 6 pages Tyme Technologies, Inc. Nonqualified Stock Option Agreement

12/34/56

EX-10.1

from 8-K 9 pages Tyme Technologies, Inc. 2016 Stock Option Plan for Non-Employee Directors as Amended and Restated Effective August 24, 2021

12/34/56

EX-10.18

from 10-K 7 pages C O N F I D E N T I a L Separation and General Release Agreement

12/34/56

EX-10.1

from 8-K 33 pages Securities Purchase Agreement

12/34/56

EX-10.2

from 10-Q 12 pages Recitals

12/34/56

EX-10.1

from 10-Q 29 pages Mr. Richard Cunningham [Redacted] [Redacted]

12/34/56

EX-10.2

from 10-Q 5 pages Ben Taylor September 20, 2020 1. Services

12/34/56

EX-10.20

from 10-K 38 pages Co-Promotion Agreement by and Between Tyme Technologies, Inc. and Eagle Pharmaceuticals, Inc. January 7, 2020

12/34/56